117 related articles for article (PubMed ID: 22109640)
1. Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment.
Niikura N; Kimura M; Iwamoto T; Hayashi N; Shintoku J; Saito Y; Suzuki Y; Tokuda Y
Breast Cancer; 2013 Jan; 20(1):67-74. PubMed ID: 22109640
[TBL] [Abstract][Full Text] [Related]
2. Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.
Duric VM; Butow PN; Sharpe L; Boyle F; Beith J; Wilcken NR; Heritier S; Coates AS; John Simes R; Stockler MR
Psychooncology; 2007 Jan; 16(1):48-59. PubMed ID: 16856128
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
4. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile.
Duric V; Stockler M
Lancet Oncol; 2001 Nov; 2(11):691-7. PubMed ID: 11902540
[TBL] [Abstract][Full Text] [Related]
5. Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer.
Duric VM; Butow PN; Sharpe L; Heritier S; Boyle F; Beith J; Wilcken NR; Coates AS; Simes RJ; Stockler MR
Patient Educ Couns; 2008 Aug; 72(2):239-45. PubMed ID: 18434070
[TBL] [Abstract][Full Text] [Related]
6. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
8. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
[TBL] [Abstract][Full Text] [Related]
12. Discrepancy between preference and actual adjuvant therapy for breast cancer.
Wood ME; Fama TA; Ashikaga T; Muss HB
Clin Breast Cancer; 2010 Oct; 10(5):398-403. PubMed ID: 20920985
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
14. Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.
; Blinman P; Mileshkin L; Khaw P; Goss G; Johnson C; Capp A; Brooks S; Wain G; Kolodziej I; Veillard AS; O'Connell R; Creutzberg CL; Stockler MR
Br J Cancer; 2016 Nov; 115(10):1179-1185. PubMed ID: 27764842
[TBL] [Abstract][Full Text] [Related]
15. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
[TBL] [Abstract][Full Text] [Related]
16. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
Hillner BE; Smith TJ
J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
[No Abstract] [Full Text] [Related]
17. Justifying adjuvant chemotherapy in breast cancer: a survey of women and healthcare professionals.
Sweeney KJ; Ryan E; Canney M; O'Daly BJ; Kerin MJ
Eur J Surg Oncol; 2007 Sep; 33(7):838-42. PubMed ID: 17267166
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?
Blinman P; Duric V; Nowak AK; Beale P; Clarke S; Briscoe K; Boyce A; Goldstein D; Hudson M; Stockler M
Eur J Cancer; 2010 Jul; 46(10):1800-7. PubMed ID: 20137908
[TBL] [Abstract][Full Text] [Related]
19. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
20. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?
Duric VM; Stockler MR; Heritier S; Boyle F; Beith J; Sullivan A; Wilcken N; Coates AS; Simes RJ
Ann Oncol; 2005 Nov; 16(11):1786-94. PubMed ID: 16126738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
